332,275 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Kelly Lawrence W & Associates Inc. CA

Posted by Geri Gentry on Aug 25th, 2026

Kelly Lawrence W & Associates Inc. CA acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 332,275 shares of the company’s stock, valued at approximately $11,520,000. Hims & Hers Health makes up about 2.5% of Kelly Lawrence W & Associates Inc. CA’s holdings, making the stock its 16th largest position.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after buying an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after acquiring an additional 319 shares in the last quarter. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $28,000. Bogart Wealth LLC increased its holdings in shares of Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the 1st quarter valued at approximately $30,000. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Stock Down 8.0%

Shares of Hims & Hers Health stock opened at $31.07 on Tuesday. The stock has a market capitalization of $7.25 billion, a price-to-earnings ratio of -49.33 and a beta of 2.40. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The business’s 50 day simple moving average is $32.39 and its 200-day simple moving average is $26.18.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same quarter in the prior year, the firm earned $0.17 EPS. The company’s revenue for the quarter was up 38.2% compared to the same quarter last year. Equities research analysts forecast that Hims & Hers Health, Inc. will post -0.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on HIMS shares. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. TD Cowen boosted their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research note on Tuesday, August 11th. Citigroup dropped their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Truist Financial raised their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a research report on Monday. Finally, UBS Group set a $23.00 price target on shares of Hims & Hers Health in a report on Friday, May 22nd. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $32.50.

Read Our Latest Report on HIMS

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Deborah M. Autor sold 16,773 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total transaction of $467,128.05. Following the completion of the transaction, the insider directly owned 48,961 shares of the company’s stock, valued at $1,363,563.85. The trade was a 25.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 55,383 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.09, for a total transaction of $1,943,389.47. Following the completion of the sale, the chief financial officer owned 228,938 shares in the company, valued at $8,033,434.42. The trade was a 19.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 186,769 shares of company stock valued at $6,035,648. Company insiders own 11.76% of the company’s stock.

Hims & Hers Health Company Profile

(Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.